Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Earnings Results, Beats Estimates By $0.12 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) released its quarterly earnings data on Monday. The biotechnology company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.12, FiscalAI reports. Enanta Pharmaceuticals had a negative return on equity of 90.35% and a negative net margin of 106.80%.The company had revenue of $18.62 million for the quarter, compared to analysts’ expectations of $16.14 million.

Enanta Pharmaceuticals Stock Up 2.2%

Shares of NASDAQ:ENTA opened at $14.13 on Wednesday. The firm’s 50 day moving average price is $14.11 and its 200-day moving average price is $11.39. Enanta Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $17.15. The stock has a market capitalization of $410.05 million, a PE ratio of -4.42 and a beta of 0.98.

Insider Activity at Enanta Pharmaceuticals

In other news, insider Yat Sun Or sold 2,390 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $34,009.70. Following the transaction, the insider owned 371,392 shares in the company, valued at $5,284,908.16. This trade represents a 0.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Tara Lynn Kieffer sold 2,106 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $29,968.38. Following the sale, the insider directly owned 30,620 shares of the company’s stock, valued at approximately $435,722.60. The trade was a 6.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 11,961 shares of company stock worth $170,149. 11.48% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio boosted its stake in Enanta Pharmaceuticals by 8.3% during the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after buying an additional 1,100 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 1,383 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Enanta Pharmaceuticals by 13.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock worth $197,000 after acquiring an additional 1,940 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Enanta Pharmaceuticals by 4.3% during the 2nd quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock worth $475,000 after purchasing an additional 2,607 shares during the period. Finally, Marshall Wace LLP grew its holdings in Enanta Pharmaceuticals by 0.8% during the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after purchasing an additional 6,522 shares during the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.